Mount Sinai Receives $500,000 SU2C grant to identify therapeutic combinations for KRAS-mutant lung cancers - Stand Up To Cancer

News

Mount Sinai Receives $500,000 SU2C grant to identify therapeutic combinations for KRAS-mutant lung cancers

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.